Outsourcing Insights: Booming Biopharma Pipeline Straining CRO Capacity - Venture capital support for biopharma is strong, helping to boost CRO utilization to its limits - BioPharm International


Outsourcing Insights: Booming Biopharma Pipeline Straining CRO Capacity
Venture capital support for biopharma is strong, helping to boost CRO utilization to its limits

BioPharm International
Volume 20, Issue 5

Reports from the annual meeting of the Society for Toxicology (SOT), held in March, indicate the problem. Analysts covering the meeting estimate that the preclinical services market is growing at the rate of 15 –20% per year, the fastest of any contract services sector. The growth is driven by the many candidates in early development and the increased willingness of major pharmaceutical companies to outsource their toxicology testing. Analyst reports note that increased demand from several major pharmaceutical companies (including Pfizer, which is closing several sites where preclinical testing is conducted) could overwhelm the market this year.

Preclinical CROs are adding capacity, but this may not be fast enough to absorb growing demand. One analyst estimates that announced new facilities and expansion plans will increase capacity by 15–20%, but it will take another two to four years for that capacity to come on stream. Biopharmaceutical companies are investigating new sources of supply in Asia, but are finding that compliance with good laboratory practices (GLPs) and animal welfare practices are still not up to Western requirements.

The capacity shortages are taking a toll on biopharmaceutical development efforts. Companies are being forced to reserve toxicology testing slots up to six months in advance, a long lead time for acute toxicology testing. Development budgets are being impacted by price increases of up to 5% annually.

CROs are using the supply and demand imbalance as leverage in negotiating long-term dedicated capacity deals with the major pharmaceutical companies. These deals are seldom good for the client, as they usually result in their paying for capacity they aren't using, but many companies are anxious to avoid the risk of not having access to preclinical capacity.

Clinical research service providers are also enjoying strong demand for their services. Exhibitors at April's "Partnerships with CROs" conference expressed considerable satisfaction with the current state of their market. While the large, publicly-traded CROs are reporting record backlogs (expected future revenues based on signed contracts), the smaller CROs are reporting strong growth thanks to the early-stage companies and overflow from the large CROs. One indicator of the good times for the smaller CROs is the intense interest in the sector being shown by private equity investors, who are actively looking for acquisitions in the industry.

For biopharmaceutical companies, however, the strong clinical CRO business has its costs. While there is no indication of an upward spiral in prices as yet, competition for key staff like site monitors is intense and costly. Further, patient recruitment has become very difficult, such that prolonged efforts to enroll patients are delaying the completion of trials. Another problem to watch out for: rapid growth at smaller CROs may outstrip their project management capabilities and the executive talents of their founders.

The bottom line: good times for biopharma are translating into good times for the CRO industry. But if there is such a thing as "too much of a good thing," the CRO industry may soon experience it.

Jim Miller is president of PharmSource Information Services, Springfield, VA, 703.383.4903,

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here